Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)

GERMANTOWN, Md., April 5, 2023 /PRNewswire/ -- Deka Biosciences ("Deka"), a clinical-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced today that the first subject…

Continue ReadingDeka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)

Next-generation targeted cytokine therapy to be explored on advancements series

JUPITER, Fla., Feb. 27, 2020 /PRNewswire-PRWeb/ -- An upcoming episode of Advancements with Ted Danson, scheduled to broadcast 2Q/2020, will explore innovative treatment solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn's Disease (Crohn's), and Oncology. Check local listings for more info.

Continue ReadingNext-generation targeted cytokine therapy to be explored on advancements series